在多巴胺激动剂治疗中患有高血糖性血症的患者的冲动控制障碍 - - 我们应该有多担心呢?
Ghazal Daftari1, Nicholas A Tritos1
1Neuroendocrine Unit and Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital and; Harvard Medical School, Boston, MA 02114, USA.
概括
用于益生菌瘤的多巴胺激动剂可以在7.5%至46%的患者中引起冲动控制障碍 (ICD). 早期检测和管理对于患者的福祉至关重要.
科学领域:
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
背景情况:
- 多巴胺激动剂 (DAs) 如卡伯戈林和布罗莫克里普丁是治疗前乳腺瘤的首要疗法.
- 冲动控制障碍 (ICD) 是DA的未被认可的不良影响,表现为强迫行为.
- ICDs可以显著损害患者和家人的生活质量.
研究的目的:
- 审查DA上的超分泌症患者的ICD的患病率,危险因素,病理生理学,诊断和管理.
主要方法:
- 进行了全面的电子文献搜索,以确定相关研究.
主要成果:
- 在DA患者中,ICD的患病率在7.5%至46%之间,卡贝戈林更频繁地参与其中.
- 风险因素包括年龄较小,男性性别和遗传多态性. 诊断工具可用于识别.
- 管理可能涉及剂量降低,停止DA或精神病学干预.
结论:
- 在用DA治疗高血糖性血症时,ICD是一个重大问题,需要提高认识和管理.
- 需要进一步的研究来了解风险因素,机制和最佳治疗策略.
相关概念视频
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
188
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
188
01:28Drug Therapy
28
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
28
01:30Attention-Deficit/Hyperactivity Disorder
21
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
21
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:26Psychosis: Goals of Pharmacotherapy
95
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
95